Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis

Therapeutic Advances in Respiratory Disease

Volumn 6, Issue 6, 2012, Pages 363-373

  Hurley, Matthew ^a   Smyth, Alan ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

antibiotics; bronchopulmonary disease; cystic fibrosis; fluoroquinolones; pseudomonas aeruginosa; pulmonary exacerbations

Indexed keywords

AMIKACIN; ANTIARRHYTHMIC AGENT; AZLOCILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CINOXACIN; CIPROFLOXACIN; COLISTIN; ENOXACIN; FLEROXACIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GENTAMICIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MANNITOL; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TOBRAMYCIN; TOSUFLOXACIN; TROVAFLOXACIN; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTHROPATHY; CARDIOTOXICITY; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERADICATION THERAPY; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HEADACHE; HIGH RISK PATIENT; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; LIVER FAILURE; LUNG INFECTION; MAINTENANCE THERAPY; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; PHOTOSENSITIVITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QT PROLONGATION; RASH; RETINA DETACHMENT; REVIEW; STAPHYLOCOCCUS AUREUS; SUICIDAL IDEATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOLOGICAL AVAILABILITY; CYSTIC FIBROSIS; FLUOROQUINOLONES; HUMANS; LUNG DISEASES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84870165826     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465812459899     Document Type: Review

References (54)

1. Adefurin A. Sammons H. Jacqz-Aigrain E. Choonara I. (2011) Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child 96: 874–880.
2. Aitken M. Bellon G. De Boeck K. Flume P. Fox H. Geller D. (2012) Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 185: 645–652.
3. Bearden D. Danziger L. (2001) Mechanism of action of and resistance to quinolones. Pharmacotherapy 21: 224S–232S.
4. Bilton D. Robinson P. Cooper P. Gallagher C. Kolbe J. Fox H. (2011) Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Resp J 38: 1071–1080.
5. Black A. Redmond A. Scott E. (1989) Randomised study comparing courses of oral ciprofloxacin alone with intermittent courses of intravenous azlocillin plus tobramycin or oral ciprofloxacin in the treatment of acute exacerbations of respiratory infection in cystic fibrosis [Abstract]. 16th Annual Meeting of the European Working Group for Cystic Fibrosis; 1989; Prague, Czechoslovakia: 31.
6. Blau H. Klein K. Shalit I. Halperin D. Fabian I. (2007) Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line. Am J Physiol Lung Cell Mol Physiol 292: L343–L352.
7. Bosso J. A. (1989) Use of ciprofloxacin in cystic fibrosis patients. Am J Med 87: 123S–127S.
8. Bosso J. A. Black P. G. Matsen J.M. (1987) Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. Am J Med 82: 180–184.
9. Chalumeau M. Tonnelier S. D'Athis P. Treluyer J. Gendrel D. Breart G. (2003) Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France. Pediatrics 111: e714–e719.
10. Christensson B. Nilsson-Ehle I. Ljungberg B. Lindblad A. Malmborg A. Hjelte L. (1992) Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother 36: 2512–2517.
11. Church D. Kanga J. Kuhn R. Rubio T. Spohn W. Stevens J. (1997) Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. Pediatr Infect Dis J 16: 97–105.
12. de Boer K. Vandemheen K. Tullis E. Doucette S. Fergusson D. Freitag A. (2011) Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 66: 680–685.
13. Elborn J. Prescott R. Stack B. Goodchild M. Bates J. Pantin C. (2000) Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 55: 355–358.
14. Etminan M. Forooghian F. Brophy J. Bird S. Maberley D. (2012) Oral fluoroquinolones and the risk of retinal detachment. JAMA 307: 1414–1419.
15. Fothergill J. Mowat E. Ledson M. Walshaw M. Winstanley C. (2010) Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations. J Med Microbiol 59: 472–481.
16. Geller D. Flume P. Staab D. Fischer R. Loutit J. Conrad D. (2011) Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Resp Crit Care Med 183: 1510–1516.
17. Gibson R. Emerson J. McNamara S. Burns J. Rosenfeld M. Yunker A. (2003) Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 167: 841–849.
18. Hansen C. Pressler T. Hoiby N. (2008) Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 7: 523–530.
19. Hodson M. E. Roberts C. M. Butland R. J. Smith M.J. Batten J.C. (1987) Oral ciprofloxacin compared with conventional intravenous treatment for pseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet 1: 235–237.
20. Hurley M. Ariff A. Bertenshaw C. Bhatt J. Smyth A. (2012a) Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. J Cyst Fibros 11: 288–292.
21. Hurley M. Prayle A. Flume P. (2012b) Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis (Protocol). Cochrane Database Syst Rev 3: CD009730.
22. Jensen T. Pedersen S.S. Hoiby N. Koch C. (1987a) Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis. Eur J Clin Microbiol 6: 618–622.
23. Jensen T. Pedersen S. S. Nielsen C. H. Hoiby N. Koch C. (1987b) The efficacy and safety of ciprofloxacin and ofloxacin in chronic pseudomonas aeruginosa infection in cystic fibrosis. J Antimicrob Chemother 20: 585–594.
24. King P. Citron D. Griffith D. Lomovskaya O. Dudley M. (2010) Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients. Diagn Microbiol Infect Dis 66: 181–186.
25. Konstan M. Flume P. Kappler M. Chiron R. Higgins M. Brockhaus F. (2011) Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 10: 54–61.
26. Labay-Kamara U. Manning S. McMahon T. (2012) Fluoroquinolone-induced suicidal ideation and suicidality. Psychosomatics 53: 97–98.
27. Langton-Hewer S. Smyth A. (2009) Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 4: CD004197.
28. Lapi F. Tuccori M. Motola D. Pugi A. Vietri M. Montanaro N. (2010) Safety profile of the fluoroquinolones: analysis of adverse drug reactions in relation to prescription data using four regional pharmacovigilance databases in Italy. Drug Saf 33: 789–799.
29. McDermott P. Walker R. White D. (2003) Antimicrobials: modes of action and mechanisms of resistance. Int J Toxicol 22: 135–143.
30. Montgomery M. Beringer P. Aminimanizani A. Louie S. Shapiro B. Jelliffe R. (2001) Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 45: 3468–3473.
31. Muller C. Plesiat P. Jeannot K. (2011) A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and beta-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother 55: 1211–1221.
32. Pedersen S. Jensen T. Hvidberg E. (1987) Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. J Antimicrob Chemother 20: 575–583.
33. Pompilio A. Catavitello C. Picciani C. Confalone P. Piccolomini R. Savini V. (2010) Subinhibitory concentrations of moxifloxacin decrease adhesion and biofilm formation of Stenotrophomonas maltophilia from cystic fibrosis. J Med Microbiol 59: 76–81.
34. Ratjen F. Doring G. Nikolaizik W. (2001) Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 358: 983–984.
35. Ratjen F. Munck A. Kho P. Angyalosi G. (2010) Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 65: 286–291.
36. Renau T. Léger R. Yen R. She M. Flamme E. Sangalang J. (2002) Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorg Med Chem Lett 12: 763–766.
37. Rogers G. Stressmann F. Koller G. Daniels T. Carroll M. Bruce K. (2008) Assessing the diagnostic importance of nonviable bacterial cells in respiratory infections. Diagn Microbiol Infect Dis 62: 133–141.
38. Rosenfeld M. Emerson J. Williams-Warren J. Pepe M. Smith A. Montgomery A. (2001) Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 139: 359–365.
39. Roveta S. Schito A. Marchese A. Schito G. (2005) Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa. Int J Antimicrob Agents 26: 366–372.
40. Rubio T. Miles M. Lettieri J. Kuhn R. Echols R. Church D. (1997) Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. Pediatr Infect Dis J 16: 112–117; discussion 123–126.
41. Ryan G. Singh M. Dwan K. (2011) Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev 3: CD001021.
42. Schaad U. B. Wedgwood-Krucko J. Guenin K. Buehlmann U. Kraemer R. (1989) Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. Eur J Clin Microbiol Infect Dis 8: 858–865.
43. Schaad U. B. Wedgwood J. Ruedeberg A. Kraemer R. Hampel B. (1997) Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. Pediatr Infect Dis J 16: 106–111.
44. Schaefer H. Stass H. Wedgwood J. Hampel B. Fischer C. Kuhlmann J. (1996) Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. Antimicrob Agents Chemother 40: 29–34.
45. Stressmann F. Rogers G. Marsh P. Lilley A. Daniels T. Carroll M. (2011) Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? J Cyst Fibros 10: 357–365.
46. Touw D. (1998) Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharm World Sci 20: 149–160.
47. Tramper-Stranders G. Wolfs T. van Haren Noman S. van Aalderen W. Nagelkerke A. Nuijsink M. (2010) Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Thorax 65: 915–920.
48. Treggiari M. Retsch-Bogart G. Mayer-Hamblett N. Khan U. Kulich M. Kronmal R. (2011) Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 165: 847–856.
49. Tunney M. Field T. Moriarty T. Patrick S. Doering G. Muhlebach M. (2008) Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 177: 995–1001.
50. UK Cystic Fibrosis Trust (2009) Antibiotic Treatment for Cystic Fibrosis ’ Report of the UK Cystic Fibrosis Trust Antibiotic Working Group. Available at: http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/Antibiotic_treatment_for_Cystic_Fibrosis.pdf ( accessed 15 August 2012).
51. US Food and Drug Administration (2009) Questions and Answers on Trovafloxacin Public Health Advisory. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053104.htm ( accessed 15 August 2012).
52. Valerius N. H. Koch C. Hoiby N. (1991) Prevention of chronic pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 338: 725–726.
53. Wiesemann H. Steinkamp G. Ratjen F. Bauernfeind A. Przyklenk B. Doring G. (1998) Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 25: 88–92.
54. Zhanel G. Ennis K. Vercaigne L. Walkty A. Gin A. Embil J. (2002) A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 62: 13–59.